Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GMP Warning Letters: FDA Approves 55% Of Field Recommendations

Executive Summary

An FDA analysis of the agency's central review of good manufacturing practices warning letters has found the policy has been effective in creating consistency in the communications

You may also be interested in...



FDA Quality Systems Guidance To Be Modeled On Consent Decrees

FDA is modeling its upcoming quality systems guidance on manufacturing consent decrees

FDA Quality Systems Guidance To Be Modeled On Consent Decrees

FDA is modeling its upcoming quality systems guidance on manufacturing consent decrees

FDA GMP Initiative Shifts Warning Letter Review Back To Agency Centers

The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of an FDA initiative to create a risk-based approach to pharmaceutical manufacturing

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel